AXT, Inc. Announces Passing of Board Member Christine Russell
'AXT is grateful for Christine's exemplary dedication and service to our company,' said Morris Young, Chief Executive Officer. 'She brought tremendous intelligence, strategic planning and thoughtful decision-making to our board and she will be greatly missed. This is a sad moment in our history. On behalf of AXT's management and Board of Directors, we extend our sincerest condolences to her family and the breadth of Silicon Valley executives who hold her in high esteem.'
About AXT, Inc.
AXT is a material science company that develops and manufactures high-performance compound and single element semiconductor substrate wafers comprising indium phosphide (InP), gallium arsenide (GaAs) and germanium (Ge). The company's substrate wafers are used when a typical silicon substrate wafer cannot meet the performance requirements of a semiconductor or optoelectronic device. End markets include 5G infrastructure, data center connectivity (silicon photonics), passive optical networks, LED lighting, lasers, sensors, power amplifiers for wireless devices and satellite solar cells. AXT's worldwide headquarters are in Fremont, California and includes sales, administration and customer service functions. AXT has its Asia headquarters in Beijing, China and manufacturing facilities in three separate locations in China. In addition, as part of its supply chain strategy, the Company has partial ownership in ten companies in China producing raw materials for its manufacturing process. For more information, see AXT's website at http://www.axt.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Coeur Mining, Inc. (CDE) Presents Bullish Case for Rochester Mine at RBC Capital Markets Global Mining & Materials Conference
With strong billionaire interest, Coeur Mining, Inc. (NYSE:CDE) is included in our list of the . A closeup view of a large gold mine, illustrating the company's gold properties. In June, Coeur Mining, Inc. (NYSE:CDE) attended the RBC Capital Markets Global Mining & Materials Conference, presenting a bullish case for the multi-asset producer, the Rochester mine, which is set to demonstrate a solid performance. The mine, which recently underwent an upgrade, is now in its first full year of operations at this new, larger scale. Rochester is expected to expand margins by significantly boosting silver output and cutting costs. Furthermore, the addition of high-grade, low-cost production through Las Chispas has expanded the company's portfolio. Coeur Mining, Inc. (NYSE:CDE)'s proven and probable reserves are up 66% over five years, thanks to its $77-$93 million budget for 2025. With a reduction in net debt/EBITDA to 0.9x and expectations of EBITDA doubling in the next year, the company is well placed for strong future growth. The company's share price is up 62.24% on a YTD basis. With Palmarejo, Rochester, Kensington, Wharf, Silvertip, and Las Chispas segments, Coeur Mining, Inc. (NYSE:CDE) operates as a gold and silver producer in the United States, Canada, and Mexico. It is included in our list of the best gold stocks. While we acknowledge the potential of CDE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 14 Cheap Transportation Stocks to Buy According to Analysts and 10 Cheap Lithium Stocks to Buy According to Hedge Funds. Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
25 minutes ago
- Yahoo
Reddit (RDDT) Is on a Roll: Analyst Hike Follows Strong Q1 and AI Upgrades
Reddit, Inc. (NYSE:RDDT) is one of the . On July 23, Needham analyst Laura Martin raised the price target on the stock to $165.00 from $145.00, while maintaining a 'Buy' rating. The rating affirmation follows Reddit's first quarter 2025 results, which exceeded consensus expectations. The firm's channel checks reveal continued strength going into the second quarter of 2025. In particular, the company has been benefiting from strong daily active user trends, growing ad monetization backed by direct-response advertisements, and an inclination toward full-funnel advertisers. brett-jordan-0FytazjHhxs-unsplash Reddit Search and Reddit Answers, new products by Reddit, are anticipated to enhance content discovery and increase user engagement times. Reddit, Inc. (NYSE:RDDT) is a social media platform that leverages AI to strengthen search functionality and improve user engagement. While we acknowledge the potential of RDDT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.
Yahoo
25 minutes ago
- Yahoo
Kyverna Appoints New CFO to Guide Next Growth Phase
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) is one of the 11 Best New Penny Stocks to Buy Right Now. On June 30, Kyverna Therapeutics, Inc. (NASDAQ:KYTX) announced that Marc Grasso, M.D. has been appointed as the company's new Chief Financial Officer (CFO). Before joining Kyverna Therapeutics, Inc. (NASDAQ:KYTX), Dr. Grasso was serving as CFO at Alector, Inc., a biotechnology company focused on neurodegenerative diseases. There, he oversaw financial planning, investor relations, accounting, IT, and facilities. Dr. Grasso earned his medical degree from Johns Hopkins University School of Medicine, where he also performed research in molecular oncology. He holds a Bachelor of Arts degree in molecular biology with honors from Princeton University. A lab setting filled with scientific equipment and researchers in lab coats working together to develop new therapies for autoimmune diseases. Dr. Grasso has over 25 years of experience working with public companies, capital markets, and investment banking. He is taking over from Ryan Jones, MBA, who is moving to a strategic advisor role to help with a smooth transition. The new CFO is expected to use his experience to help Kyverna Therapeutics, Inc. (NASDAQ:KYTX) bring the first CAR T-cell therapy for autoimmune diseases to the market while also guiding the company's business and financial plans. As Kyverna Therapeutics, Inc. (NASDAQ:KYTX) works to speed up its clinical development and commercialization efforts, Dr. Grasso's leadership will play a crucial role in supporting the company's next phase of growth. Kyverna Therapeutics, Inc. (NASDAQ:KYTX) is a clinical-stage biopharmaceutical company committed to developing cell therapies for patients suffering from autoimmune diseases. While we acknowledge the potential of KYTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
